Puma Biotechnology, Inc. — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012. Unaudited financial statements; the company was a development-stage biopharmaceutical business with no product revenue.
Business context and outlook
Puma licenses and develops cancer drug candidates: oral and intravenous PB272 (neratinib) and PB357, a potential backup compound. The company focused on transitioning clinical-trial responsibilities for neratinib from its licensor and building its operating infrastructure. Management said product approval was not expected until approximately 2015, assuming no unforeseen safety issues.
Key financial metrics
| Metric | Q2 2012 / June 30, 2012 | Comparable period / prior balance |
|---|---|---|
| Revenue | No product sales | No product sales |
| Operating expenses | $14.78 million for Q2; $26.63 million for six months | $34,265 for Q2 2011; $38,206 for six months 2011 |
| Net loss | $14.75 million for Q2; $26.58 million for six months | $34,265 for Q2 2011; $38,206 for six months 2011 |
| Q2 loss per share | $0.74, basic and diluted | $0.009 for Q2 2011 |
| Cash and cash equivalents | $41.00 million | $53.38 million at December 31, 2011 |
| Operating cash flow | $(8.77) million for Q2; $(11.56) million for six months | $(39,935) for six months 2011 |
| Working capital | $26.29 million | Not stated for the comparable prior balance |
| Total liabilities | $16.40 million, including $15.54 million current liabilities | $1.03 million at December 31, 2011 |
| Debt | No debt balance reported | — |
R&D expense was $13.01 million in Q2 and $23.57 million for the first half; G&A was $1.70 million and $2.94 million, respectively. The filing reports no product revenue, so revenue margins are not meaningful. Cash used in investing activities was $0.82 million for the first half; there was no financing cash flow in that period.
Material changes and unusual items
- Losses and spending rose sharply from 2011, when the company had not yet begun meaningful operations. The periods are therefore not directly comparable as measures of an established operating business.
- First-half accrued expenses reached $13.13 million, including $10.75 million in estimated licensor transition costs and $1.30 million in clinical costs. The increase in payables and accruals helped make operating cash outflow substantially lower than net loss; accrued estimates may be adjusted as actual costs become known.
- Management estimated approximately $3 million of duplicate clinical-trial costs during the transition from the licensor to the company and its CRO; it expected these costs to cease after the transition was completed.
- First-half G&A included a $214,591 reduction in the estimated value of the CEO’s anti-dilutive warrant. The warrant’s value remains subject to remeasurement until its grant date is determined.
- The company entered a seven-year South San Francisco office lease expected to begin around October 1, 2012. First-year base rent is approximately $20,250 monthly; $157,000 of restricted cash collateralizes a $150,000 letter of credit.
Liquidity, risks, and management commentary
Management said cash on hand was expected to fund anticipated expenditures for at least the next 12 months. For the next 12 months, it estimated R&D spending of $30–$35 million and G&A spending of $5–$6 million. It also stated that additional financing would be needed thereafter until profitability, if achieved. There were no committed financing sources; future funding could require equity or debt, a strategic alliance, or other sources, and may not be available on acceptable terms or at all. A funding shortfall could force delays or reductions in development programs.
Key risks include clinical-trial outcomes and costs, regulatory approval, dependence on external clinical and manufacturing providers, the need for additional capital, potential shareholder dilution, and the possibility that products may never be commercialized. The company reported no pending or threatened legal proceedings, no material change in previously disclosed risk factors, and effective disclosure controls as of June 30, 2012.
Important facts for investors to verify
- Whether the licensor-to-company clinical-trial transition was completed and whether estimated transition accruals were later revised or paid.
- Whether the $41.00 million cash balance and stated 12-month runway supported the planned development pace and spending estimates.
- Clinical progress, enrollment, safety results, and regulatory milestones for oral and intravenous neratinib and PB357.
- Availability and terms of future financing or a strategic partnership, including potential dilution.
- How the CEO warrant valuation and the new lease obligations affect subsequent-period expenses, cash, and equity.